FDA Accepts Ragweed Therapy BLA.
The AP (5/9) reports Merck & Co.said Wednesday that the Food and Drug Administration has accepted for review its "second application" for its investigational allergy immunotherapy tablet, which "dissolves under the tongue." The first biologics license application Merck submitted in March, was for a grass pollen sublingual allergy immunotherapy tablet and this latest one is for a ragweed pollen sublingual allergy immunotherapy tablet. The Whitehouse Station, New Jersey-based pharmaceutical company said it expects FDA rulings on both BLAs "of the still-unnamed treatments in the first half of next year."
